ID   ABL1_HUMAN              Reviewed;        1130 AA.
AC   P00519; A3KFJ3; Q13869; Q13870; Q16133; Q17R61; Q45F09;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 4.
DT   22-JUL-2015, entry version 216.
DE   RecName: Full=Tyrosine-protein kinase ABL1;
DE            EC=2.7.10.2;
DE   AltName: Full=Abelson murine leukemia viral oncogene homolog 1;
DE   AltName: Full=Abelson tyrosine-protein kinase 1;
DE   AltName: Full=Proto-oncogene c-Abl;
DE   AltName: Full=p150;
GN   Name=ABL1; Synonyms=ABL, JTK7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA), ALTERNATIVE SPLICING, AND
RP   VARIANT PRO-140.
RX   PubMed=3021337; DOI=10.1016/0092-8674(86)90450-2;
RA   Shtivelman E., Lifshitz B., Gale R.P., Roe B.A., Canaani E.;
RT   "Alternative splicing of RNAs transcribed from the human abl gene and
RT   from the bcr-abl fused gene.";
RL   Cell 47:277-284(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IA).
RC   TISSUE=Fibroblast;
RX   PubMed=2687768;
RA   Fainstein E., Einat M., Gokkel E., Marcelle C., Croce C.M., Gale R.P.,
RA   Canaani E.;
RT   "Nucleotide sequence analysis of human abl and bcr-abl cDNAs.";
RL   Oncogene 4:1477-1481(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS IA AND IB).
RC   TISSUE=Lung;
RX   PubMed=7665185; DOI=10.1006/geno.1995.1008;
RA   Chissoe S.L., Bodenteich A., Wang Y.-F., Wang Y.-P., Burian D.,
RA   Clifton S.W., Crabtree J., Freeman A., Iyer K., Jian L., Ma Y.,
RA   McLaury H.-J., Pan H.-Q., Sarhan O.H., Toth S., Wang Z., Zhang G.,
RA   Heisterkamp N., Groffen J., Roe B.A.;
RT   "Sequence and analysis of the human ABL gene, the BCR gene, and
RT   regions involved in the Philadelphia chromosomal translocation.";
RL   Genomics 27:67-82(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-706; PRO-852;
RP   SER-900 AND LEU-972.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IB).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-40, AND SUBCELLULAR COMPONENT.
RX   PubMed=2825022; DOI=10.1038/330386a0;
RA   Fainstein E., Marcelle C., Rosner A., Canaani E., Gale R.P.,
RA   Dreazen O., Smith S.D., Croce C.M.;
RT   "A new fused transcript in Philadelphia chromosome positive acute
RT   lymphocytic leukaemia.";
RL   Nature 330:386-388(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 360-426.
RX   PubMed=6191223; DOI=10.1038/304167a0;
RA   Groffen J., Heisterkamp N., Reynolds F.H. Jr., Stephenson J.R.;
RT   "Homology between phosphotyrosine acceptor site of human c-abl and
RT   viral oncogene products.";
RL   Nature 304:167-169(1983).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 825-845.
RX   PubMed=7545908;
RA   Inokuchi K., Futaki M., Dan K., Nomura T.;
RT   "Sequence analysis of the mutation at codon 834 and the sequence
RT   variation of codon 837 of c-abl gene.";
RL   Leukemia 8:343-344(1994).
RN   [11]
RP   MYRISTOYLATION AT GLY-2 (ISOFORM IB).
RX   PubMed=2542016;
RA   Jackson P., Baltimore D.;
RT   "N-terminal mutations activate the leukemogenic potential of the
RT   myristoylated form of c-abl.";
RL   EMBO J. 8:449-456(1989).
RN   [12]
RP   DOMAIN, AND DNA-BINDING.
RX   PubMed=2183353; DOI=10.1126/science.2183353;
RA   Kipreos E.T., Wang J.Y.;
RT   "Differential phosphorylation of c-Abl in cell cycle determined by
RT   cdc2 kinase and phosphatase activity.";
RL   Science 248:217-220(1990).
RN   [13]
RP   FUNCTION.
RX   PubMed=9037071; DOI=10.1073/pnas.94.4.1437;
RA   Yuan Z.M., Huang Y., Ishiko T., Kharbanda S., Weichselbaum R.,
RA   Kufe D.;
RT   "Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:1437-1440(1997).
RN   [14]
RP   INTERACTION WITH RIN1, AND FUNCTION.
RX   PubMed=9144171; DOI=10.1073/pnas.94.10.4954;
RA   Han L., Wong D., Dhaka A., Afar D.E.H., White M., Xie W.,
RA   Herschman H., Witte O., Colicelli J.;
RT   "Protein binding and signaling properties of RIN1 suggest a unique
RT   effector function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:4954-4959(1997).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH RAD51.
RX   PubMed=9461559; DOI=10.1074/jbc.273.7.3799;
RA   Yuan Z.M., Huang Y., Ishiko T., Nakada S., Utsugisawa T.,
RA   Kharbanda S., Wang R., Sung P., Shinohara A., Weichselbaum R.,
RA   Kufe D.;
RT   "Regulation of Rad51 function by c-Abl in response to DNA damage.";
RL   J. Biol. Chem. 273:3799-3802(1998).
RN   [16]
RP   INTERACTION WITH INPPL1.
RX   PubMed=10194451;
RA   Wisniewski D., Strife A., Swendeman S., Erdjument-Bromage H.,
RA   Geromanos S., Kavanaugh W.M., Tempst P., Clarkson B.;
RT   "A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-
RT   phosphatase (SHIP2) is constitutively tyrosine phosphorylated and
RT   associated with src homologous and collagen gene (SHC) in chronic
RT   myelogenous leukemia progenitor cells.";
RL   Blood 93:2707-2720(1999).
RN   [17]
RP   FUNCTION, ENZYME REGULATION, AND INTERACTION WITH TP73.
RX   PubMed=10391250; DOI=10.1038/21697;
RA   Agami R., Blandino G., Oren M., Shaul Y.;
RT   "Interaction of c-Abl and p73alpha and their collaboration to induce
RT   apoptosis.";
RL   Nature 399:809-813(1999).
RN   [18]
RP   DNA-BINDING.
RX   PubMed=10325413; DOI=10.1093/nar/27.11.2265;
RA   David-Cordonnier M.H., Payet D., D'Halluin J.C., Waring M.J.,
RA   Travers A.A., Bailly C.;
RT   "The DNA-binding domain of human c-Abl tyrosine kinase promotes the
RT   interaction of a HMG chromosomal protein with DNA.";
RL   Nucleic Acids Res. 27:2265-2270(1999).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=11114745; DOI=10.1038/sj.onc.1203878;
RA   Wang J.Y.;
RT   "Regulation of cell death by the Abl tyrosine kinase.";
RL   Oncogene 19:5643-5650(2000).
RN   [20]
RP   INTERACTION WITH SORBS1.
RX   PubMed=11374898; DOI=10.1006/geno.2001.6541;
RA   Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y.,
RA   Chuang L.-M.;
RT   "Cloning, mapping, and characterization of the human sorbin and SH3
RT   domain containing 1 (SORBS1) gene: a protein associated with c-Abl
RT   during insulin signaling in the hepatoma cell line Hep3B.";
RL   Genomics 74:12-20(2001).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH RAD52.
RX   PubMed=12379650; DOI=10.1074/jbc.M208151200;
RA   Kitao H., Yuan Z.M.;
RT   "Regulation of ionizing radiation-induced Rad52 nuclear foci formation
RT   by c-Abl-mediated phosphorylation.";
RL   J. Biol. Chem. 277:48944-48948(2002).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH RAD9A.
RX   PubMed=11971963; DOI=10.1128/MCB.22.10.3292-3300.2002;
RA   Yoshida K., Komatsu K., Wang H.-G., Kufe D.;
RT   "c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in
RT   response to DNA damage.";
RL   Mol. Cell. Biol. 22:3292-3300(2002).
RN   [23]
RP   UBIQUITINATION.
RX   PubMed=12475393; DOI=10.1042/BJ20021539;
RA   Soubeyran P., Barac A., Szymkiewicz I., Dikic I.;
RT   "Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-
RT   Abl.";
RL   Biochem. J. 370:29-34(2003).
RN   [24]
RP   FUNCTION.
RX   PubMed=12531427; DOI=10.1016/S0898-6568(02)00090-6;
RA   Sanguinetti A.R., Mastick C.C.;
RT   "c-Abl is required for oxidative stress-induced phosphorylation of
RT   caveolin-1 on tyrosine 14.";
RL   Cell. Signal. 15:289-298(2003).
RN   [25]
RP   FUNCTION.
RX   PubMed=12672821; DOI=10.1074/jbc.M301447200;
RA   Tani K., Sato S., Sukezane T., Kojima H., Hirose H., Hanafusa H.,
RA   Shishido T.;
RT   "Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian
RT   enabled (Mena) by c-Abl kinase.";
RL   J. Biol. Chem. 278:21685-21692(2003).
RN   [26]
RP   REVIEW ON FUNCTION.
RX   PubMed=12775773; DOI=10.1242/jcs.00622;
RA   Woodring P.J., Hunter T., Wang J.Y.;
RT   "Regulation of F-actin-dependent processes by the Abl family of
RT   tyrosine kinases.";
RL   J. Cell Sci. 116:2613-2626(2003).
RN   [27]
RP   INTERACTION WITH BCR.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster
RT   region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-
RT   dependent manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [28]
RP   FUNCTION.
RX   PubMed=15556646; DOI=10.1016/j.febslet.2004.10.054;
RA   Grossmann A.H., Kolibaba K.S., Willis S.G., Corbin A.S., Langdon W.S.,
RA   Deininger M.W., Druker B.J.;
RT   "Catalytic domains of tyrosine kinases determine the phosphorylation
RT   sites within c-Cbl.";
RL   FEBS Lett. 577:555-562(2004).
RN   [29]
RP   FUNCTION.
RX   PubMed=15031292; DOI=10.1074/jbc.M311479200;
RA   Perkinton M.S., Standen C.L., Lau K.F., Kesavapany S., Byers H.L.,
RA   Ward M., McLoughlin D.M., Miller C.C.;
RT   "The c-Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to
RT   stimulate Fe65/amyloid precursor protein nuclear signaling.";
RL   J. Biol. Chem. 279:22084-22091(2004).
RN   [30]
RP   REVIEW ON FUNCTION.
RX   PubMed=15686624; DOI=10.1038/sj.cr.7290261;
RA   Shaul Y., Ben-Yehoyada M.;
RT   "Role of c-Abl in the DNA damage stress response.";
RL   Cell Res. 15:33-35(2005).
RN   [31]
RP   FUNCTION.
RX   PubMed=15886098; DOI=10.1016/j.cub.2005.03.049;
RA   Hu H., Bliss J.M., Wang Y., Colicelli J.;
RT   "RIN1 is an ABL tyrosine kinase activator and a regulator of
RT   epithelial-cell adhesion and migration.";
RL   Curr. Biol. 15:815-823(2005).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH CASP9.
RX   PubMed=15657060; DOI=10.1074/jbc.M413787200;
RA   Raina D., Pandey P., Ahmad R., Bharti A., Ren J., Kharbanda S.,
RA   Weichselbaum R., Kufe D.;
RT   "c-Abl tyrosine kinase regulates caspase-9 autocleavage in the
RT   apoptotic response to DNA damage.";
RL   J. Biol. Chem. 280:11147-11151(2005).
RN   [33]
RP   INTERACTION WITH YWHAB; YWHAE; YWHAG; YWHAH; SFN AND YWHAZ,
RP   PHOSPHORYLATION AT THR-735, IDENTIFICATION BY MASS SPECTROMETRY,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-735.
RX   PubMed=15696159; DOI=10.1038/ncb1228;
RA   Yoshida K., Yamaguchi T., Natsume T., Kufe D., Miki Y.;
RT   "JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of
RT   c-Abl in the apoptotic response to DNA damage.";
RL   Nat. Cell Biol. 7:278-285(2005).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [35]
RP   ACETYLATION AT LYS-711, AND SUBCELLULAR LOCATION.
RX   PubMed=16648821; DOI=10.1038/sj.embor.7400700;
RA   di Bari M.G., Ciuffini L., Mingardi M., Testi R., Soddu S., Barila D.;
RT   "c-Abl acetylation by histone acetyltransferases regulates its
RT   nuclear-cytoplasmic localization.";
RL   EMBO Rep. 7:727-733(2006).
RN   [36]
RP   PHOSPHORYLATION AT TYR-70; TYR-115; TYR-128; TYR-139; TYR-172; TYR-185
RP   TYR-215; TYR-226 AND TYR-393, INTERACTION WITH HCK; LYN AND FYN, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16912036; DOI=10.1074/jbc.M605902200;
RA   Meyn M.A. III, Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P.,
RA   Wu J., Hochrein J.M., Engen J.R., Smithgall T.E.;
RT   "Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and
RT   modulate Bcr-Abl transforming activity.";
RL   J. Biol. Chem. 281:30907-30916(2006).
RN   [37]
RP   FUNCTION.
RX   PubMed=16943190; DOI=10.1074/jbc.M603126200;
RA   Tanos B., Pendergast A.M.;
RT   "Abl tyrosine kinase regulates endocytosis of the epidermal growth
RT   factor receptor.";
RL   J. Biol. Chem. 281:32714-32723(2006).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH PSMA7.
RX   PubMed=16678104; DOI=10.1016/j.molcel.2006.04.007;
RA   Liu X., Huang W., Li C., Li P., Yuan J., Li X., Qiu X.B., Ma Q.,
RA   Cao C.;
RT   "Interaction between c-Abl and Arg tyrosine kinases and proteasome
RT   subunit PSMA7 regulates proteasome degradation.";
RL   Mol. Cell 22:317-327(2006).
RN   [39]
RP   FUNCTION.
RX   PubMed=17306540; DOI=10.1016/j.cub.2007.01.057;
RA   Boyle S.N., Michaud G.A., Schweitzer B., Predki P.F., Koleske A.J.;
RT   "A critical role for cortactin phosphorylation by Abl-family kinases
RT   in PDGF-induced dorsal-wave formation.";
RL   Curr. Biol. 17:445-451(2007).
RN   [40]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH WASF3.
RX   PubMed=17623672; DOI=10.1074/jbc.M701484200;
RA   Sossey-Alaoui K., Li X., Cowell J.K.;
RT   "c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia
RT   formation and cell migration.";
RL   J. Biol. Chem. 282:26257-26265(2007).
RN   [41]
RP   PHOSPHORYLATION AT SER-618 AND SER-619, AND INTERACTION WITH ABI2 AND
RP   CRK.
RX   PubMed=18161990; DOI=10.1021/bi701533j;
RA   Jung J.H., Pendergast A.M., Zipfel P.A., Traugh J.A.;
RT   "Phosphorylation of c-Abl by protein kinase Pak2 regulates
RT   differential binding of ABI2 and CRK.";
RL   Biochemistry 47:1094-1104(2008).
RN   [42]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=18328268; DOI=10.1016/j.bbamcr.2008.01.028;
RA   Xiong X., Cui P., Hossain S., Xu R., Warner B., Guo X., An X.,
RA   Debnath A.K., Cowburn D., Kotula L.;
RT   "Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase
RT   by phosphopeptides derived from Abi1/Hssh3bp1.";
RL   Biochim. Biophys. Acta 1783:737-747(2008).
RN   [43]
RP   FUNCTION.
RX   PubMed=18945674; DOI=10.1074/jbc.M804543200;
RA   Yogalingam G., Pendergast A.M.;
RT   "Abl kinases regulate autophagy by promoting the trafficking and
RT   function of lysosomal components.";
RL   J. Biol. Chem. 283:35941-35953(2008).
RN   [44]
RP   PHOSPHORYLATION AT TYR-70, AND INTERACTION WITH ABI1.
RX   PubMed=18775435; DOI=10.1016/j.jmb.2008.08.040;
RA   Chen S., O'Reilly L.P., Smithgall T.E., Engen J.R.;
RT   "Tyrosine phosphorylation in the SH3 domain disrupts negative
RT   regulatory interactions within the c-Abl kinase core.";
RL   J. Mol. Biol. 383:414-423(2008).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50; SER-569; SER-659;
RP   THR-814; THR-844 AND SER-977, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; THR-852 AND
RP   SER-917, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [47]
RP   REVIEW ON FUNCTION.
RX   PubMed=18182299; DOI=10.1016/j.tibs.2007.10.006;
RA   Backert S., Feller S.M., Wessler S.;
RT   "Emerging roles of Abl family tyrosine kinases in microbial
RT   pathogenesis.";
RL   Trends Biochem. Sci. 33:80-90(2008).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [49]
RP   FUNCTION.
RX   PubMed=19891780; DOI=10.1186/1471-2121-10-80;
RA   Fernow I., Tomasovic A., Siehoff-Icking A., Tikkanen R.;
RT   "Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src
RT   kinases.";
RL   BMC Cell Biol. 10:80-80(2009).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [51]
RP   IDENTIFICATION IN A COMPLEX WITH UNC119; ABL2 AND CRK.
RX   PubMed=19381274; DOI=10.1371/journal.pone.0005211;
RA   Vepachedu R., Karim Z., Patel O., Goplen N., Alam R.;
RT   "Unc119 protects from Shigella infection by inhibiting the Abl family
RT   kinases.";
RL   PLoS ONE 4:E5211-E5211(2009).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50 AND SER-569, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [53]
RP   FUNCTION.
RX   PubMed=20417104; DOI=10.1016/j.cub.2010.03.048;
RA   Michael M., Vehlow A., Navarro C., Krause M.;
RT   "c-Abl, Lamellipodin, and Ena/VASP proteins cooperate in dorsal
RT   ruffling of fibroblasts and axonal morphogenesis.";
RL   Curr. Biol. 20:783-791(2010).
RN   [54]
RP   INTERACTION WITH MYLK AND CTTN.
RX   PubMed=20861316; DOI=10.1091/mbc.E09-10-0876;
RA   Dudek S.M., Chiang E.T., Camp S.M., Guo Y., Zhao J., Brown M.E.,
RA   Singleton P.A., Wang L., Desai A., Arce F.T., Lal R., Van Eyk J.E.,
RA   Imam S.Z., Garcia J.G.N.;
RT   "Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain
RT   kinase to regulate endothelial barrier function.";
RL   Mol. Biol. Cell 21:4042-4056(2010).
RN   [55]
RP   REVIEW ON FUNCTION, AND DOMAIN.
RX   PubMed=20841568; DOI=10.1126/scisignal.3139re6;
RA   Colicelli J.;
RT   "ABL tyrosine kinases: evolution of function, regulation, and
RT   specificity.";
RL   Sci. Signal. 3:RE6-RE6(2010).
RN   [56]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [57]
RP   INTERACTION WITH STX17.
RX   PubMed=23006999; DOI=10.1016/j.bbamcr.2012.09.003;
RA   Muppirala M., Gupta V., Swarup G.;
RT   "Tyrosine phosphorylation of a SNARE protein, Syntaxin 17:
RT   Implications for membrane trafficking in the early secretory
RT   pathway.";
RL   Biochim. Biophys. Acta 1823:2109-2119(2012).
RN   [58]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [59]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   PubMed=1505033; DOI=10.1016/0092-8674(92)90437-H;
RA   Overduin M., Rios C.B., Mayer B.J., Baltimore D., Cowburn D.;
RT   "Three-dimensional solution structure of the src homology 2 domain of
RT   c-abl.";
RL   Cell 70:697-704(1992).
RN   [60]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   PubMed=1281542; DOI=10.1073/pnas.89.24.11673;
RA   Overduin M., Mayer B.J., Rios C.B., Baltimore D., Cowburn D.;
RT   "Secondary structure of Src homology 2 domain of c-Abl by
RT   heteronuclear NMR spectroscopy in solution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:11673-11677(1992).
RN   [61]
RP   3D-STRUCTURE MODELING OF SH3 DOMAIN.
RX   PubMed=7892170; DOI=10.1002/prot.340200302;
RA   Pisabarro M.T., Ortiz A.R., Serrano L., Wade R.C.;
RT   "Homology modeling of the Abl-SH3 domain.";
RL   Proteins 20:203-215(1994).
RN   [62]
RP   STRUCTURE BY NMR OF SH3 DOMAIN.
RX   PubMed=8590002; DOI=10.1016/S0969-2126(01)00243-X;
RA   Gosser Y.Q., Zheng J., Overduin M., Mayer B.J., Cowburn D.;
RT   "The solution structure of Abl SH3, and its relationship to SH2 in the
RT   SH(32) construct.";
RL   Structure 3:1075-1086(1995).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 64-121.
RX   PubMed=9698566; DOI=10.1006/jmbi.1998.1932;
RA   Pisabarro M.T., Serrano L., Wilmanns M.;
RT   "Crystal structure of the abl-SH3 domain complexed with a designed
RT   high-affinity peptide ligand: implications for SH3-ligand
RT   interactions.";
RL   J. Mol. Biol. 281:513-521(1998).
RN   [64]
RP   STRUCTURE BY NMR OF 62-122 IN COMPLEX WITH CRK.
RX   PubMed=12384576; DOI=10.1073/pnas.212518799;
RA   Donaldson L.W., Gish G., Pawson T., Kay L.E., Forman-Kay J.D.;
RT   "Structure of a regulatory complex involving the Abl SH3 domain, the
RT   Crk SH2 domain, and a Crk-derived phosphopeptide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14053-14058(2002).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (3.42 ANGSTROMS) OF 27-512, MYRISTOYLATION AT
RP   GLY-2 (ISOFORM IB), ENZYME REGULATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=12654251; DOI=10.1016/S0092-8674(03)00194-6;
RA   Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D.,
RA   Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J.;
RT   "Structural basis for the autoinhibition of c-Abl tyrosine kinase.";
RL   Cell 112:859-871(2003).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 229-513 OF MUTANT PRO-396 IN
RP   COMPLEX WITH INHIBITOR VX-680, FUNCTION, AND ENZYME REGULATION.
RX   PubMed=16424036; DOI=10.1158/0008-5472.CAN-05-2788;
RA   Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V.,
RA   Biggs W.H. III, Treiber D.K., Patel H.K., Zarrinkar P.P.,
RA   Lockhart D.J., Sawyers C.L., Kuriyan J.;
RT   "Structure of the kinase domain of an imatinib-resistant Abl mutant in
RT   complex with the Aurora kinase inhibitor VX-680.";
RL   Cancer Res. 66:1007-1014(2006).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 38-512, IDENTIFICATION BY
RP   MASS SPECTROMETRY, MYRISTOYLATION AT GLY-2 (ISOFORM IB),
RP   PHOSPHORYLATION AT SER-50, AUTOINHIBITORY MECHANISM, AND ENZYME
RP   REGULATION.
RX   PubMed=16543148; DOI=10.1016/j.molcel.2006.01.035;
RA   Nagar B., Hantschel O., Seeliger M., Davies J.M., Weis W.I.,
RA   Superti-Furga G., Kuriyan J.;
RT   "Organization of the SH3-SH2 unit in active and inactive forms of the
RT   c-Abl tyrosine kinase.";
RL   Mol. Cell 21:787-798(2006).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 229-512 IN COMPLEXES WITH
RP   ATP-PEPTIDE CONJUGATE, AND CONFORMATION CHANGES DURING ACTIVATION.
RX   PubMed=16640460; DOI=10.1371/journal.pbio.0040144;
RA   Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M.,
RA   Karplus M., Cole P.A., Kuriyan J.;
RT   "A Src-like inactive conformation in the abl tyrosine kinase domain.";
RL   PLoS Biol. 4:E144-E144(2006).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 229-500 IN COMPLEXES WITH
RP   IMATINIB AND WITH THE INHIBITORS NVP-AEG082; NVP-AFN941; NVP-AFG210
RP   AND PD180970.
RX   PubMed=17164530; DOI=10.1107/S0907444906047287;
RA   Cowan-Jacob S.W., Fendrich G., Floersheimer A., Furet P.,
RA   Liebetanz J., Rummel G., Rheinberger P., Centeleghe M., Fabbro D.,
RA   Manley P.W.;
RT   "Structural biology contributions to the discovery of drugs to treat
RT   chronic myelogenous leukaemia.";
RL   Acta Crystallogr. D 63:80-93(2007).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 64-121 OF MUTANT ALA-114 IN
RP   COMPLEX WITH PROLINE-RICH PEPTIDE.
RX   PubMed=17452790; DOI=10.1107/S0907444907011109;
RA   Camara-Artigas A., Palencia A., Martinez J.C., Luque I., Gavira J.A.,
RA   Garcia-Ruiz J.M.;
RT   "Crystallization by capillary counter-diffusion and structure
RT   determination of the N114A mutant of the SH3 domain of Abl tyrosine
RT   kinase complexed with a high-affinity peptide ligand.";
RL   Acta Crystallogr. D 63:646-652(2007).
RN   [71]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 60-121 IN COMPLEX WITH
RP   PROLINE-RICH PEPTIDE P41.
RX   PubMed=19906645; DOI=10.1074/jbc.M109.048033;
RA   Palencia A., Camara-Artigas A., Pisabarro M.T., Martinez J.C.,
RA   Luque I.;
RT   "Role of interfacial water molecules in proline-rich ligand
RT   recognition by the Src homology 3 domain of Abl.";
RL   J. Biol. Chem. 285:2823-2833(2010).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 121-232 IN COMPLEX WITH
RP   ANTIBODY MIMIC HA4, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20357770; DOI=10.1038/nsmb.1793;
RA   Wojcik J., Hantschel O., Grebien F., Kaupe I., Bennett K.L.,
RA   Barkinge J., Jones R.B., Koide A., Superti-Furga G., Koide S.;
RT   "A potent and highly specific FN3 monobody inhibitor of the Abl SH2
RT   domain.";
RL   Nat. Struct. Mol. Biol. 17:519-527(2010).
RN   [73]
RP   VARIANTS GLY-47; LYS-166; VAL-706; LEU-810 AND LEU-972.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays a role
CC       in many key processes linked to cell growth and survival such as
CC       cytoskeleton remodeling in response to extracellular stimuli, cell
CC       motility and adhesion, receptor endocytosis, autophagy, DNA damage
CC       response and apoptosis. Coordinates actin remodeling through
CC       tyrosine phosphorylation of proteins controlling cytoskeleton
CC       dynamics like WASF3 (involved in branch formation); ANXA1
CC       (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH
CC       (involved in signaling); or MAPT and PXN (microtubule-binding
CC       proteins). Phosphorylation of WASF3 is critical for the
CC       stimulation of lamellipodia formation and cell migration. Involved
CC       in the regulation of cell adhesion and motility through
CC       phosphorylation of key regulators of these processes such as
CC       BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple
CC       receptor tyrosine kinases and more particularly promotes
CC       endocytosis of EGFR, facilitates the formation of neuromuscular
CC       synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and
CC       modulates the endocytosis of activated B-cell receptor complexes.
CC       Other substrates which are involved in endocytosis regulation are
CC       the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL
CC       family of ubiquitin ligases that drive receptor down-regulation
CC       and actin remodeling. Phosphorylation of CBL leads to increased
CC       EGFR stability. Involved in late-stage autophagy by regulating
CC       positively the trafficking and function of lysosomal components.
CC       ABL1 targets to mitochondria in response to oxidative stress and
CC       thereby mediates mitochondrial dysfunction and cell death. ABL1 is
CC       also translocated in the nucleus where it has DNA-binding activity
CC       and is involved in DNA-damage response and apoptosis. Many
CC       substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3,
CC       ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic
CC       pathway when the DNA damage is too severe to be repaired.
CC       Phosphorylates TP73, a primary regulator for this type of damage-
CC       induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153'
CC       and regulates its processing in the apoptotic response to DNA
CC       damage. Phosphorylates PSMA7 that leads to an inhibition of
CC       proteasomal activity and cell cycle transition blocks. ABL1 acts
CC       also as a regulator of multiple pathological signaling cascades
CC       during infection. Several known tyrosine-phosphorylated microbial
CC       proteins have been identified as ABL1 substrates. This is the case
CC       of A36R of Vaccinia virus, Tir (translocated intimin receptor) of
CC       pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-
CC       associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing
CC       protein A) of A.phagocytophilum. Pathogens can highjack ABL1
CC       kinase signaling to reorganize the host actin cytoskeleton for
CC       multiple purposes, like facilitating intracellular movement and
CC       host cell exit. Finally, functions as its own regulator through
CC       autocatalytic activity as well as through phosphorylation of its
CC       inhibitor, ABI1. {ECO:0000269|PubMed:10391250,
CC       ECO:0000269|PubMed:11971963, ECO:0000269|PubMed:12379650,
CC       ECO:0000269|PubMed:12531427, ECO:0000269|PubMed:12672821,
CC       ECO:0000269|PubMed:15031292, ECO:0000269|PubMed:15556646,
CC       ECO:0000269|PubMed:15657060, ECO:0000269|PubMed:15886098,
CC       ECO:0000269|PubMed:16424036, ECO:0000269|PubMed:16678104,
CC       ECO:0000269|PubMed:16943190, ECO:0000269|PubMed:17306540,
CC       ECO:0000269|PubMed:17623672, ECO:0000269|PubMed:18328268,
CC       ECO:0000269|PubMed:18945674, ECO:0000269|PubMed:19891780,
CC       ECO:0000269|PubMed:20357770, ECO:0000269|PubMed:20417104,
CC       ECO:0000269|PubMed:9037071, ECO:0000269|PubMed:9144171,
CC       ECO:0000269|PubMed:9461559}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:20357770}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC   -!- ENZYME REGULATION: Stabilized in the inactive form by an
CC       association between the SH3 domain and the SH2-TK linker region,
CC       interactions of the N-terminal cap, and contributions from an N-
CC       terminal myristoyl group and phospholipids. Activated by
CC       autophosphorylation as well as by SRC-family kinase-mediated
CC       phosphorylation. Activated by RIN1 binding to the SH2 and SH3
CC       domains. Also stimulated by cell death inducers and DNA-damage.
CC       Phosphatidylinositol 4,5-bisphosphate (PIP2), a highly abundant
CC       phosphoinositide known to regulate cytoskeletal and membrane
CC       proteins, inhibits also the tyrosine kinase activity (By
CC       similarity). Inhibited by ABI1, whose activity is controlled by
CC       ABL1 itself through tyrosine phosphorylation. Also inhibited by
CC       imatinib mesylate (Gleevec) which is used for the treatment of
CC       chronic myeloid leukemia (CML), and by VX-680, an inhibitor that
CC       acts also on imatinib-resistant mutants. {ECO:0000250,
CC       ECO:0000269|PubMed:10391250, ECO:0000269|PubMed:12654251,
CC       ECO:0000269|PubMed:16424036, ECO:0000269|PubMed:16543148,
CC       ECO:0000269|PubMed:18328268}.
CC   -!- SUBUNIT: Interacts with SORBS1 following insulin stimulation.
CC       Found in a trimolecular complex containing CDK5 and CABLES1.
CC       Interacts with CABLES1 and PSTPIP1. Interacts with ZDHHC16, ITGB1
CC       and HCK (By similarity). Interacts with STX17; probably
CC       phosphorylates STX17. Interacts with INPPL1/SHIP2. Interacts with
CC       the 14-3-3 proteins, YWHAB, YWHAE, YWHAG, YWHAH, SFN AND YWHAZ;
CC       the interaction with 14-3-3 proteins requires phosphorylation on
CC       Thr-735 and, sequesters ABL1 into the cytoplasm. Interacts with
CC       ABI1, ABI2, BCR, CRK, FGR, FYN, HCK, LYN, PSMA7 RAD9A, RAD51,
CC       RAD52, TP73 and WASF3. A complex made of ABL1, CTTN and MYLK
CC       regulates cortical actin-based cytoskeletal rearrangement critical
CC       to sphingosine 1-phosphate (S1P)-mediated endothelial cell (EC)
CC       barrier enhancement. Interacts (via SH3 domain) with CASP9; the
CC       interaction is direct and increases in the response of cells to
CC       genotoxic stress and ABL1/c-Abl activation. Found in a complex
CC       with ABL1, ABL2, CRK and UNC119; leading to the inhibition of CRK
CC       phosphorylation by ABL kinases. {ECO:0000250,
CC       ECO:0000269|PubMed:10194451, ECO:0000269|PubMed:10391250,
CC       ECO:0000269|PubMed:11374898, ECO:0000269|PubMed:11971963,
CC       ECO:0000269|PubMed:12379650, ECO:0000269|PubMed:12384576,
CC       ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15657060,
CC       ECO:0000269|PubMed:15696159, ECO:0000269|PubMed:16424036,
CC       ECO:0000269|PubMed:16678104, ECO:0000269|PubMed:16912036,
CC       ECO:0000269|PubMed:17452790, ECO:0000269|PubMed:17623672,
CC       ECO:0000269|PubMed:18161990, ECO:0000269|PubMed:18775435,
CC       ECO:0000269|PubMed:19381274, ECO:0000269|PubMed:19906645,
CC       ECO:0000269|PubMed:20357770, ECO:0000269|PubMed:20861316,
CC       ECO:0000269|PubMed:23006999, ECO:0000269|PubMed:9144171,
CC       ECO:0000269|PubMed:9461559}.
CC   -!- INTERACTION:
CC       Q8IZP0:ABI1; NbExp=11; IntAct=EBI-375543, EBI-375446;
CC       Q9NYB9:ABI2; NbExp=2; IntAct=EBI-375543, EBI-743598;
CC       P10275:AR; NbExp=2; IntAct=EBI-375543, EBI-608057;
CC       Q4KMG0:CDON; NbExp=2; IntAct=EBI-375543, EBI-7016840;
CC       O35158:Cdon (xeno); NbExp=4; IntAct=EBI-375543, EBI-7016767;
CC       P46108:CRK; NbExp=2; IntAct=EBI-375543, EBI-886;
CC       P46109:CRKL; NbExp=2; IntAct=EBI-375543, EBI-910;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-375543, EBI-491549;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-375543, EBI-297353;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-375543, EBI-641062;
CC       Q14315:FLNC; NbExp=2; IntAct=EBI-375543, EBI-489954;
CC       P05107:ITGB2; NbExp=4; IntAct=EBI-375543, EBI-300173;
CC       P10721:KIT; NbExp=2; IntAct=EBI-375543, EBI-1379503;
CC       Q38SD2:LRRK1; NbExp=3; IntAct=EBI-375543, EBI-1050422;
CC       Q92918:MAP4K1; NbExp=3; IntAct=EBI-375543, EBI-881;
CC       Q7Z434:MAVS; NbExp=6; IntAct=EBI-375543, EBI-995373;
CC       O43196:MSH5; NbExp=10; IntAct=EBI-375543, EBI-6092730;
CC       P15941:MUC1; NbExp=8; IntAct=EBI-375543, EBI-2804728;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-375543, EBI-389883;
CC       O43900:PRICKLE3; NbExp=2; IntAct=EBI-375543, EBI-1751761;
CC       Q13905:RAPGEF1; NbExp=4; IntAct=EBI-375543, EBI-976876;
CC       Q86UR5:RIMS1; NbExp=2; IntAct=EBI-375543, EBI-1043236;
CC       Q13671:RIN1; NbExp=4; IntAct=EBI-375543, EBI-366017;
CC       P31947:SFN; NbExp=2; IntAct=EBI-375543, EBI-476295;
CC       Q15464:SHB; NbExp=5; IntAct=EBI-375543, EBI-4402156;
CC       O75751:SLC22A3; NbExp=2; IntAct=EBI-375543, EBI-1752674;
CC       Q9BX66:SORBS1; NbExp=2; IntAct=EBI-375543, EBI-433642;
CC       O60504-2:SORBS3; NbExp=5; IntAct=EBI-375543, EBI-1222956;
CC       Q07890:SOS2; NbExp=2; IntAct=EBI-375543, EBI-298181;
CC       P12931:SRC; NbExp=2; IntAct=EBI-375543, EBI-621482;
CC       Q9Y4G6:TLN2; NbExp=3; IntAct=EBI-375543, EBI-1220811;
CC       P11387:TOP1; NbExp=7; IntAct=EBI-375543, EBI-876302;
CC       P15498:VAV1; NbExp=5; IntAct=EBI-375543, EBI-625518;
CC       P63104:YWHAZ; NbExp=3; IntAct=EBI-375543, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton. Nucleus.
CC       Mitochondrion {ECO:0000250}. Note=Shuttles between the nucleus and
CC       cytoplasm depending on environmental signals. Sequestered into the
CC       cytoplasm through interaction with 14-3-3 proteins. Localizes to
CC       mitochondria in response to oxidative stress (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform IB: Nucleus membrane; Lipid-anchor.
CC       Note=The myristoylated c-ABL protein is reported to be nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=IA;
CC         IsoId=P00519-1; Sequence=Displayed;
CC       Name=IB;
CC         IsoId=P00519-2; Sequence=VSP_004957;
CC         Note=Contains a N-myristoyl glycine at position 2.;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: Acetylated at Lys-711 by EP300 which promotes the cytoplasmic
CC       translocation. {ECO:0000269|PubMed:16648821}.
CC   -!- PTM: Phosphorylation at Tyr-70 by members of the SRC family of
CC       kinases disrupts SH3 domain-based autoinhibitory interactions and
CC       intermolecular associations, such as that with ABI1, and also
CC       enhances kinase activity. Phosphorylation at Tyr-226 and Tyr-393
CC       correlate with increased activity. DNA damage-induced activation
CC       of ABL1 requires the function of ATM and Ser-446 phosphorylation
CC       (By similarity). Phosphorylation at Ser-569 has been attributed to
CC       a CDC2-associated kinase and is coupled to cell division (By
CC       similarity). Phosphorylation at Ser-618 and Ser-619 by PAK2
CC       increases binding to CRK and reduces binding to ABI1.
CC       Phosphorylation on Thr-735 is required for binding 14-3-3 proteins
CC       for cytoplasmic translocation. Phosphorylated by PRKDC (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated. Polyubiquitination of ABL1 leads to
CC       degradation. {ECO:0000269|PubMed:12475393}.
CC   -!- DISEASE: Leukemia, chronic myeloid (CML) [MIM:608232]: A clonal
CC       myeloproliferative disorder of a pluripotent stem cell with a
CC       specific cytogenetic abnormality, the Philadelphia chromosome
CC       (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid,
CC       and sometimes T-lymphoid cells, but not marrow fibroblasts.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Note=A chromosomal aberration involving ABL1 has been
CC       found in patients with chronic myeloid leukemia. Translocation
CC       t(9;22)(q34;q11) with BCR. The translocation produces a BCR-ABL
CC       found also in acute myeloid leukemia (AML) and acute lymphoblastic
CC       leukemia (ALL).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. ABL subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 SH2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -!- SIMILARITY: Contains 1 SH3 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00192}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABL.html";
CC   -!- WEB RESOURCE: Name=CGP resequencing studies;
CC       URL="http://www.sanger.ac.uk/perl/genetics/CGP/cgp_viewer?action=gene&ln=ABL1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abl1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Abl entry;
CC       URL="http://en.wikipedia.org/wiki/Abl_gene";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14752; AAA51561.1; -; mRNA.
DR   EMBL; X16416; CAA34438.1; -; mRNA.
DR   EMBL; U07563; AAB60394.1; -; Genomic_DNA.
DR   EMBL; U07563; AAB60393.1; -; Genomic_DNA.
DR   EMBL; U07561; AAB60393.1; JOINED; Genomic_DNA.
DR   EMBL; DQ145721; AAZ38718.1; -; Genomic_DNA.
DR   EMBL; AL359092; CAM45752.1; -; Genomic_DNA.
DR   EMBL; AL161733; CAM45752.1; JOINED; Genomic_DNA.
DR   EMBL; AL161733; CAM45754.1; -; Genomic_DNA.
DR   EMBL; AL161733; CAM45756.1; -; Genomic_DNA.
DR   EMBL; AL359092; CAM45756.1; JOINED; Genomic_DNA.
DR   EMBL; CH471090; EAW87948.1; -; Genomic_DNA.
DR   EMBL; BC117451; AAI17452.1; -; mRNA.
DR   EMBL; S69223; AAD14034.1; -; Genomic_DNA.
DR   CCDS; CCDS35165.1; -. [P00519-2]
DR   CCDS; CCDS35166.1; -. [P00519-1]
DR   PIR; S08519; TVHUA.
DR   RefSeq; NP_005148.2; NM_005157.5. [P00519-1]
DR   RefSeq; NP_009297.2; NM_007313.2. [P00519-2]
DR   UniGene; Hs.431048; -.
DR   PDB; 1AB2; NMR; -; A=120-220.
DR   PDB; 1ABL; Model; -; A=65-121.
DR   PDB; 1AWO; NMR; -; A=65-119.
DR   PDB; 1BBZ; X-ray; 1.65 A; A/C/E/G=64-121.
DR   PDB; 1JU5; NMR; -; C=62-122.
DR   PDB; 1OPL; X-ray; 3.42 A; A/B=27-512.
DR   PDB; 1ZZP; NMR; -; A=1007-1130.
DR   PDB; 2ABL; X-ray; 2.50 A; A=57-218.
DR   PDB; 2E2B; X-ray; 2.20 A; A/B=229-515.
DR   PDB; 2F4J; X-ray; 1.91 A; A=229-513.
DR   PDB; 2FO0; X-ray; 2.27 A; A=38-512.
DR   PDB; 2G1T; X-ray; 1.80 A; A/B/C/D=229-512.
DR   PDB; 2G2F; X-ray; 2.70 A; A/B=229-512.
DR   PDB; 2G2H; X-ray; 2.00 A; A/B=229-512.
DR   PDB; 2G2I; X-ray; 3.12 A; A/B=229-512.
DR   PDB; 2GQG; X-ray; 2.40 A; A/B=229-500.
DR   PDB; 2HIW; X-ray; 2.20 A; A/B=230-512.
DR   PDB; 2HYY; X-ray; 2.40 A; A/B/C/D=228-500.
DR   PDB; 2HZ0; X-ray; 2.10 A; A/B=228-497.
DR   PDB; 2HZ4; X-ray; 2.80 A; A/B/C=228-500.
DR   PDB; 2HZI; X-ray; 1.70 A; A/B=229-500.
DR   PDB; 2O88; X-ray; 1.75 A; A/B=64-121.
DR   PDB; 2V7A; X-ray; 2.50 A; A/B=229-512.
DR   PDB; 3CS9; X-ray; 2.21 A; A/B/C/D=229-500.
DR   PDB; 3EG0; X-ray; 2.30 A; A=60-121.
DR   PDB; 3EG1; X-ray; 1.85 A; A/B=60-121.
DR   PDB; 3EG2; X-ray; 1.80 A; A=60-121.
DR   PDB; 3EG3; X-ray; 1.40 A; A=60-121.
DR   PDB; 3EGU; X-ray; 2.25 A; A=60-121.
DR   PDB; 3K2M; X-ray; 1.75 A; A/B=121-232.
DR   PDB; 3PYY; X-ray; 1.85 A; A/B=229-512.
DR   PDB; 3QRI; X-ray; 2.10 A; A/B=229-499.
DR   PDB; 3QRJ; X-ray; 1.82 A; A/B=229-499.
DR   PDB; 3QRK; X-ray; 2.30 A; A=229-499.
DR   PDB; 3T04; X-ray; 2.10 A; A=112-232.
DR   PDB; 3UE4; X-ray; 2.42 A; A/B=229-512.
DR   PDB; 3UYO; X-ray; 1.83 A; A=112-232.
DR   PDB; 4J9B; X-ray; 1.70 A; A=60-121.
DR   PDB; 4J9C; X-ray; 1.05 A; A=60-121.
DR   PDB; 4J9D; X-ray; 1.50 A; A/C/E=60-121.
DR   PDB; 4J9E; X-ray; 1.40 A; A/C/E=60-121.
DR   PDB; 4J9F; X-ray; 1.09 A; A/C/E=60-121.
DR   PDB; 4J9G; X-ray; 1.80 A; A/C/E=60-121.
DR   PDB; 4J9H; X-ray; 1.70 A; A/B/C/D/E/F=60-121.
DR   PDB; 4J9I; X-ray; 2.20 A; A/C/E=60-121.
DR   PDB; 4JJB; X-ray; 1.65 A; A=60-121.
DR   PDB; 4JJC; X-ray; 1.60 A; A=60-121.
DR   PDB; 4JJD; X-ray; 1.60 A; A=60-121.
DR   PDB; 4TWP; X-ray; 2.40 A; A/B=233-503.
DR   PDB; 4WA9; X-ray; 2.20 A; A/B=246-512.
DR   PDB; 4XEY; X-ray; 2.89 A; A/B=119-515.
DR   PDBsum; 1AB2; -.
DR   PDBsum; 1ABL; -.
DR   PDBsum; 1AWO; -.
DR   PDBsum; 1BBZ; -.
DR   PDBsum; 1JU5; -.
DR   PDBsum; 1OPL; -.
DR   PDBsum; 1ZZP; -.
DR   PDBsum; 2ABL; -.
DR   PDBsum; 2E2B; -.
DR   PDBsum; 2F4J; -.
DR   PDBsum; 2FO0; -.
DR   PDBsum; 2G1T; -.
DR   PDBsum; 2G2F; -.
DR   PDBsum; 2G2H; -.
DR   PDBsum; 2G2I; -.
DR   PDBsum; 2GQG; -.
DR   PDBsum; 2HIW; -.
DR   PDBsum; 2HYY; -.
DR   PDBsum; 2HZ0; -.
DR   PDBsum; 2HZ4; -.
DR   PDBsum; 2HZI; -.
DR   PDBsum; 2O88; -.
DR   PDBsum; 2V7A; -.
DR   PDBsum; 3CS9; -.
DR   PDBsum; 3EG0; -.
DR   PDBsum; 3EG1; -.
DR   PDBsum; 3EG2; -.
DR   PDBsum; 3EG3; -.
DR   PDBsum; 3EGU; -.
DR   PDBsum; 3K2M; -.
DR   PDBsum; 3PYY; -.
DR   PDBsum; 3QRI; -.
DR   PDBsum; 3QRJ; -.
DR   PDBsum; 3QRK; -.
DR   PDBsum; 3T04; -.
DR   PDBsum; 3UE4; -.
DR   PDBsum; 3UYO; -.
DR   PDBsum; 4J9B; -.
DR   PDBsum; 4J9C; -.
DR   PDBsum; 4J9D; -.
DR   PDBsum; 4J9E; -.
DR   PDBsum; 4J9F; -.
DR   PDBsum; 4J9G; -.
DR   PDBsum; 4J9H; -.
DR   PDBsum; 4J9I; -.
DR   PDBsum; 4JJB; -.
DR   PDBsum; 4JJC; -.
DR   PDBsum; 4JJD; -.
DR   PDBsum; 4TWP; -.
DR   PDBsum; 4WA9; -.
DR   PDBsum; 4XEY; -.
DR   ProteinModelPortal; P00519; -.
DR   SMR; P00519; 46-511, 1024-1130.
DR   BioGrid; 106543; 173.
DR   DIP; DIP-1042N; -.
DR   IntAct; P00519; 216.
DR   MINT; MINT-7236141; -.
DR   STRING; 9606.ENSP00000361423; -.
DR   BindingDB; P00519; -.
DR   ChEMBL; CHEMBL2111414; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   GuidetoPHARMACOLOGY; 1923; -.
DR   PhosphoSite; P00519; -.
DR   BioMuta; ABL1; -.
DR   DMDM; 85681908; -.
DR   MaxQB; P00519; -.
DR   PaxDb; P00519; -.
DR   PRIDE; P00519; -.
DR   DNASU; 25; -.
DR   Ensembl; ENST00000318560; ENSP00000323315; ENSG00000097007.
DR   Ensembl; ENST00000372348; ENSP00000361423; ENSG00000097007. [P00519-2]
DR   GeneID; 25; -.
DR   KEGG; hsa:25; -.
DR   UCSC; uc004bzv.3; human. [P00519-2]
DR   UCSC; uc004bzw.3; human. [P00519-1]
DR   CTD; 25; -.
DR   GeneCards; GC09P133589; -.
DR   HGNC; HGNC:76; ABL1.
DR   HPA; CAB002686; -.
DR   HPA; HPA027251; -.
DR   HPA; HPA027280; -.
DR   HPA; HPA028409; -.
DR   MIM; 189980; gene.
DR   MIM; 608232; phenotype.
DR   neXtProt; NX_P00519; -.
DR   Orphanet; 521; Chronic myeloid leukemia.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA24413; -.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOVERGEN; HBG004162; -.
DR   InParanoid; P00519; -.
DR   KO; K06619; -.
DR   OMA; GAFRESG; -.
DR   OrthoDB; EOG7GTT2V; -.
DR   PhylomeDB; P00519; -.
DR   TreeFam; TF105081; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; REACT_160086; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; REACT_19230; Role of Abl in Robo-Slit signaling.
DR   Reactome; REACT_21402; CDO in myogenesis.
DR   Reactome; REACT_24970; Factors involved in megakaryocyte development and platelet production.
DR   Reactome; REACT_355372; RHO GTPases Activate WASPs and WAVEs.
DR   SignaLink; P00519; -.
DR   ChiTaRS; ABL1; human.
DR   EvolutionaryTrace; P00519; -.
DR   GeneWiki; ABL_(gene); -.
DR   GenomeRNAi; 25; -.
DR   NextBio; 79; -.
DR   PMAP-CutDB; P00519; -.
DR   PRO; PR:P00519; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; P00519; -.
DR   CleanEx; HS_ABL1; -.
DR   ExpressionAtlas; P00519; baseline and differential.
DR   Genevisible; P00519; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0031252; C:cell leading edge; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:MGI.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0003785; F:actin monomer binding; TAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004515; F:nicotinate-nucleotide adenylyltransferase activity; TAS:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0070064; F:proline-rich region binding; IDA:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0019905; F:syntaxin binding; IPI:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0090135; P:actin filament branching; IEA:Ensembl.
DR   GO; GO:0050798; P:activated T cell proliferation; IEA:Ensembl.
DR   GO; GO:0046632; P:alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0002322; P:B cell proliferation involved in immune response; IEA:Ensembl.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0001922; P:B-1 B cell homeostasis; IEA:Ensembl.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0006464; P:cellular protein modification process; NAS:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:1903351; P:cellular response to dopamine; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0021587; P:cerebellum morphogenesis; IEA:Ensembl.
DR   GO; GO:0048668; P:collateral sprouting; IEA:Ensembl.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; TAS:UniProtKB.
DR   GO; GO:0030035; P:microspike assembly; IEA:Ensembl.
DR   GO; GO:0006298; P:mismatch repair; TAS:ProtInc.
DR   GO; GO:0051882; P:mitochondrial depolarization; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0007067; P:mitotic nuclear division; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0042692; P:muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:1900275; P:negative regulation of phospholipase C activity; IMP:MGI.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0051444; P:negative regulation of ubiquitin-protein transferase activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:1902715; P:positive regulation of interferon-gamma secretion; IEA:Ensembl.
DR   GO; GO:1900042; P:positive regulation of interleukin-2 secretion; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
DR   GO; GO:1901216; P:positive regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:2000096; P:positive regulation of Wnt signaling pathway, planar cell polarity pathway; IEA:Ensembl.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0030100; P:regulation of endocytosis; TAS:UniProtKB.
DR   GO; GO:1903053; P:regulation of extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:2001020; P:regulation of response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0006979; P:response to oxidative stress; IGI:MGI.
DR   GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0002333; P:transitional one stage B cell differentiation; IEA:Ensembl.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR015015; F-actin_binding.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF08919; F_actin_bind; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00808; FABD; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Autophagy; Cell adhesion; Chromosomal rearrangement;
KW   Complete proteome; Cytoplasm; Cytoskeleton; DNA damage; DNA repair;
KW   DNA-binding; Endocytosis; Kinase; Lipoprotein; Magnesium; Manganese;
KW   Membrane; Metal-binding; Mitochondrion; Myristate; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN         1   1130       Tyrosine-protein kinase ABL1.
FT                                /FTId=PRO_0000088050.
FT   DOMAIN       61    121       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      127    217       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      242    493       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     248    256       ATP.
FT   NP_BIND     316    322       ATP.
FT   REGION        1     60       CAP.
FT   REGION      869    968       DNA-binding. {ECO:0000250}.
FT   REGION      953   1130       F-actin-binding.
FT   MOTIF       381    405       Kinase activation loop.
FT   MOTIF       605    609       Nuclear localization signal 1.
FT                                {ECO:0000255}.
FT   MOTIF       709    715       Nuclear localization signal 2.
FT                                {ECO:0000255}.
FT   MOTIF       762    769       Nuclear localization signal 3.
FT                                {ECO:0000255}.
FT   MOTIF      1090   1100       Nuclear export signal. {ECO:0000250}.
FT   COMPBIAS     18     22       Poly-Ser.
FT   COMPBIAS    605    609       Poly-Lys.
FT   COMPBIAS    782   1019       Pro-rich.
FT   COMPBIAS    897    903       Poly-Pro.
FT   ACT_SITE    363    363       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     271    271       ATP.
FT   SITE         26     27       Breakpoint for translocation to form BCR-
FT                                ABL oncogene.
FT   MOD_RES      50     50       Phosphoserine.
FT                                {ECO:0000269|PubMed:16543148,
FT                                ECO:0000269|PubMed:18691976,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES      70     70       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16912036,
FT                                ECO:0000269|PubMed:18775435}.
FT   MOD_RES     115    115       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16912036}.
FT   MOD_RES     128    128       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16912036}.
FT   MOD_RES     139    139       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16912036}.
FT   MOD_RES     172    172       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16912036}.
FT   MOD_RES     185    185       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16912036}.
FT   MOD_RES     215    215       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16912036}.
FT   MOD_RES     226    226       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16912036}.
FT   MOD_RES     229    229       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P42684}.
FT   MOD_RES     393    393       Phosphotyrosine; by autocatalysis and
FT                                SRC-type Tyr-kinases.
FT                                {ECO:0000269|PubMed:16912036}.
FT   MOD_RES     446    446       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00520}.
FT   MOD_RES     569    569       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:18691976,
FT                                ECO:0000269|PubMed:19369195,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES     618    618       Phosphoserine; by PAK2.
FT                                {ECO:0000269|PubMed:18161990}.
FT   MOD_RES     619    619       Phosphoserine; by PAK2.
FT                                {ECO:0000269|PubMed:18161990}.
FT   MOD_RES     659    659       Phosphoserine.
FT                                {ECO:0000269|PubMed:18691976}.
FT   MOD_RES     711    711       N6-acetyllysine; by EP300.
FT                                {ECO:0000269|PubMed:16648821}.
FT   MOD_RES     735    735       Phosphothreonine.
FT                                {ECO:0000269|PubMed:15696159}.
FT   MOD_RES     814    814       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18691976}.
FT   MOD_RES     844    844       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18691976}.
FT   MOD_RES     852    852       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     917    917       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     977    977       Phosphoserine.
FT                                {ECO:0000269|PubMed:18691976}.
FT   VAR_SEQ       1     26       MLEICLKLVGCKSKKGLSSSSSCYLE -> MGQQPGKVLGD
FT                                QRRPSLPALHFIKGAGKKESSRHGGPHCNVFVEH (in
FT                                isoform IB).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_004957.
FT   VARIANT      47     47       R -> G (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032676.
FT   VARIANT     140    140       L -> P (in dbSNP:rs1064152).
FT                                {ECO:0000269|PubMed:3021337}.
FT                                /FTId=VAR_051692.
FT   VARIANT     166    166       R -> K (in a melanoma sample; somatic
FT                                mutation). {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032677.
FT   VARIANT     247    247       K -> R (in dbSNP:rs34549764).
FT                                /FTId=VAR_051693.
FT   VARIANT     706    706       G -> V (in dbSNP:rs34634745).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025043.
FT   VARIANT     810    810       P -> L (in dbSNP:rs2229071).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032678.
FT   VARIANT     852    852       T -> P. {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025044.
FT   VARIANT     900    900       P -> S (in dbSNP:rs35266696).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025045.
FT   VARIANT     968    968       S -> P (in dbSNP:rs1064165).
FT                                /FTId=VAR_051694.
FT   VARIANT     972    972       S -> L (in dbSNP:rs2229067).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025046.
FT   MUTAGEN     735    735       T->A: Abolishes phosphorylation. Loss of
FT                                binding YWHAS and YWHAZ. Localizes to the
FT                                nucleus. No effect on kinase activity.
FT                                {ECO:0000269|PubMed:15696159}.
FT   CONFLICT    159    159       G -> S (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    424    425       AF -> GK (in Ref. 9). {ECO:0000305}.
FT   CONFLICT    445    445       L -> R (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    459    459       E -> K (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    520    520       S -> T (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    719    719       A -> V (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    837    837       G -> E (in Ref. 2; CAA34438).
FT                                {ECO:0000305}.
FT   CONFLICT    837    837       G -> W (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    863    863       G -> R (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    894    894       R -> K (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    917    919       SPS -> RPG (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    952    952       G -> A (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    967    968       QS -> HP (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT    982    982       P -> PL (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT   1022   1022       Missing (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT   1045   1045       R -> G (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   CONFLICT   1103   1103       T -> S (in Ref. 1; AAA51561).
FT                                {ECO:0000305}.
FT   HELIX        49     53       {ECO:0000244|PDB:2FO0}.
FT   HELIX        58     60       {ECO:0000244|PDB:2FO0}.
FT   STRAND       65     70       {ECO:0000244|PDB:4J9C}.
FT   STRAND       76     79       {ECO:0000244|PDB:3EG3}.
FT   STRAND       87     93       {ECO:0000244|PDB:4J9C}.
FT   STRAND       97    104       {ECO:0000244|PDB:4J9C}.
FT   STRAND      107    112       {ECO:0000244|PDB:4J9C}.
FT   HELIX       113    115       {ECO:0000244|PDB:4J9C}.
FT   STRAND      116    118       {ECO:0000244|PDB:4J9C}.
FT   HELIX       122    124       {ECO:0000244|PDB:3K2M}.
FT   STRAND      128    131       {ECO:0000244|PDB:3K2M}.
FT   HELIX       134    140       {ECO:0000244|PDB:3K2M}.
FT   TURN        141    143       {ECO:0000244|PDB:3K2M}.
FT   STRAND      148    153       {ECO:0000244|PDB:3K2M}.
FT   STRAND      155    157       {ECO:0000244|PDB:3K2M}.
FT   STRAND      161    167       {ECO:0000244|PDB:3K2M}.
FT   STRAND      170    178       {ECO:0000244|PDB:3K2M}.
FT   TURN        180    182       {ECO:0000244|PDB:4XEY}.
FT   STRAND      184    187       {ECO:0000244|PDB:3K2M}.
FT   STRAND      192    194       {ECO:0000244|PDB:3K2M}.
FT   HELIX       195    204       {ECO:0000244|PDB:3K2M}.
FT   STRAND      209    211       {ECO:0000244|PDB:3K2M}.
FT   STRAND      226    228       {ECO:0000244|PDB:2FO0}.
FT   STRAND      229    231       {ECO:0000244|PDB:2GQG}.
FT   TURN        233    235       {ECO:0000244|PDB:2G1T}.
FT   HELIX       239    241       {ECO:0000244|PDB:2HZI}.
FT   STRAND      242    248       {ECO:0000244|PDB:2HZI}.
FT   HELIX       249    251       {ECO:0000244|PDB:2HZI}.
FT   STRAND      254    261       {ECO:0000244|PDB:2HZI}.
FT   HELIX       262    264       {ECO:0000244|PDB:2HZI}.
FT   STRAND      266    272       {ECO:0000244|PDB:2HZI}.
FT   STRAND      275    278       {ECO:0000244|PDB:2GQG}.
FT   HELIX       280    290       {ECO:0000244|PDB:2HZI}.
FT   STRAND      301    305       {ECO:0000244|PDB:2HZI}.
FT   STRAND      307    310       {ECO:0000244|PDB:2HZI}.
FT   STRAND      312    316       {ECO:0000244|PDB:2HZI}.
FT   STRAND      319    322       {ECO:0000244|PDB:2HZI}.
FT   HELIX       323    329       {ECO:0000244|PDB:2HZI}.
FT   TURN        332    334       {ECO:0000244|PDB:2HZI}.
FT   HELIX       337    356       {ECO:0000244|PDB:2HZI}.
FT   STRAND      359    361       {ECO:0000244|PDB:2G2H}.
FT   HELIX       366    368       {ECO:0000244|PDB:2HZI}.
FT   STRAND      369    371       {ECO:0000244|PDB:2HZI}.
FT   HELIX       373    375       {ECO:0000244|PDB:2HZI}.
FT   STRAND      377    379       {ECO:0000244|PDB:2HZI}.
FT   HELIX       381    383       {ECO:0000244|PDB:2G2F}.
FT   HELIX       384    387       {ECO:0000244|PDB:2G1T}.
FT   HELIX       390    392       {ECO:0000244|PDB:2G1T}.
FT   STRAND      395    401       {ECO:0000244|PDB:2G1T}.
FT   HELIX       403    405       {ECO:0000244|PDB:2HZI}.
FT   HELIX       408    413       {ECO:0000244|PDB:2HZI}.
FT   HELIX       418    433       {ECO:0000244|PDB:2HZI}.
FT   HELIX       445    447       {ECO:0000244|PDB:2HZI}.
FT   HELIX       448    453       {ECO:0000244|PDB:2HZI}.
FT   HELIX       466    475       {ECO:0000244|PDB:2HZI}.
FT   HELIX       480    482       {ECO:0000244|PDB:2HZI}.
FT   HELIX       486    499       {ECO:0000244|PDB:2HZI}.
FT   HELIX       503    506       {ECO:0000244|PDB:2G1T}.
FT   TURN        510    512       {ECO:0000244|PDB:2F4J}.
FT   HELIX      1029   1045       {ECO:0000244|PDB:1ZZP}.
FT   TURN       1046   1048       {ECO:0000244|PDB:1ZZP}.
FT   HELIX      1053   1070       {ECO:0000244|PDB:1ZZP}.
FT   HELIX      1071   1073       {ECO:0000244|PDB:1ZZP}.
FT   HELIX      1080   1097       {ECO:0000244|PDB:1ZZP}.
FT   STRAND     1101   1104       {ECO:0000244|PDB:1ZZP}.
FT   STRAND     1106   1108       {ECO:0000244|PDB:1ZZP}.
FT   HELIX      1115   1128       {ECO:0000244|PDB:1ZZP}.
SQ   SEQUENCE   1130 AA;  122873 MW;  85FE6C1C0E483EA2 CRC64;
     MLEICLKLVG CKSKKGLSSS SSCYLEEALQ RPVASDFEPQ GLSEAARWNS KENLLAGPSE
     NDPNLFVALY DFVASGDNTL SITKGEKLRV LGYNHNGEWC EAQTKNGQGW VPSNYITPVN
     SLEKHSWYHG PVSRNAAEYL LSSGINGSFL VRESESSPGQ RSISLRYEGR VYHYRINTAS
     DGKLYVSSES RFNTLAELVH HHSTVADGLI TTLHYPAPKR NKPTVYGVSP NYDKWEMERT
     DITMKHKLGG GQYGEVYEGV WKKYSLTVAV KTLKEDTMEV EEFLKEAAVM KEIKHPNLVQ
     LLGVCTREPP FYIITEFMTY GNLLDYLREC NRQEVNAVVL LYMATQISSA MEYLEKKNFI
     HRDLAARNCL VGENHLVKVA DFGLSRLMTG DTYTAHAGAK FPIKWTAPES LAYNKFSIKS
     DVWAFGVLLW EIATYGMSPY PGIDLSQVYE LLEKDYRMER PEGCPEKVYE LMRACWQWNP
     SDRPSFAEIH QAFETMFQES SISDEVEKEL GKQGVRGAVS TLLQAPELPT KTRTSRRAAE
     HRDTTDVPEM PHSKGQGESD PLDHEPAVSP LLPRKERGPP EGGLNEDERL LPKDKKTNLF
     SALIKKKKKT APTPPKRSSS FREMDGQPER RGAGEEEGRD ISNGALAFTP LDTADPAKSP
     KPSNGAGVPN GALRESGGSG FRSPHLWKKS STLTSSRLAT GEEEGGGSSS KRFLRSCSAS
     CVPHGAKDTE WRSVTLPRDL QSTGRQFDSS TFGGHKSEKP ALPRKRAGEN RSDQVTRGTV
     TPPPRLVKKN EEAADEVFKD IMESSPGSSP PNLTPKPLRR QVTVAPASGL PHKEEAGKGS
     ALGTPAAAEP VTPTSKAGSG APGGTSKGPA EESRVRRHKH SSESPGRDKG KLSRLKPAPP
     PPPAASAGKA GGKPSQSPSQ EAAGEAVLGA KTKATSLVDA VNSDAAKPSQ PGEGLKKPVL
     PATPKPQSAK PSGTPISPAP VPSTLPSASS ALAGDQPSST AFIPLISTRV SLRKTRQPPE
     RIASGAITKG VVLDSTEALC LAISRNSEQM ASHSAVLEAG KNLYTFCVSY VDSIQQMRNK
     FAFREAINKL ENNLRELQIC PATAGSGPAA TQDFSKLLSS VKEISDIVQR
//
